ABSTRACT

For the simultaneous determination of Montelukast sodium and Bilastine in combination utilising methanol as solvent, a new, simple, effective, explicit, definite, and sensitive UV spectrophotometric absorption correction method has been devised. The absorbance correction approach is based on the additive property. 252 nm and 344 nm were chosen as the wavelengths for the absorption correction technique. While Bilastine exhibited negligible absorbance at 344 nm, Montelukast sodium displayed modest absorbance. At 252 nm, both medications produced absorption. Utilizing measurements of absorbance at two wavelengths—252 nm and 344 nm—the procedure entailed calculating an equation. The approach was statistically validated. The measurements were performed using an absorbance correction method with a mean recovery of 99.33-100.34 % and 99.83-100.63 % for Montelukast sodium and Bilastine, respectively, spanning the concentration range of 2-12 g/ml for Montelukast sodium and 4-24 g/ml for Bilastine. The accuracy of the approach was determined to be within the limitations (RSD 2%) for both the same day and other days. This approach can be used for the simultaneous determination of Montelukast sodium and Bilastine in mixed dosage form and was found to be explicit, definitive, simple, sensitive, repeatable, and cost-effective.

Keywords: Montelukast Sodium, Bilastine, Absorption Correction Method